4D Molecular Therapeutics (FDMT) Current Leases (2021 - 2025)
Historic Current Leases for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $5.7 million.
- 4D Molecular Therapeutics' Current Leases rose 1186.41% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 1186.41%. This contributed to the annual value of $5.6 million for FY2024, which is 7900.92% up from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Current Leases stood at $5.7 million, which was up 1186.41% from $5.7 million recorded in Q2 2025.
- 4D Molecular Therapeutics' 5-year Current Leases high stood at $5.7 million for Q2 2025, and its period low was $1.2 million during Q4 2021.
- In the last 5 years, 4D Molecular Therapeutics' Current Leases had a median value of $3.1 million in 2023 and averaged $3.6 million.
- In the last 5 years, 4D Molecular Therapeutics' Current Leases soared by 11567.83% in 2022 and then skyrocketed by 299.71% in 2024.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Current Leases stood at $1.2 million in 2021, then skyrocketed by 115.68% to $2.7 million in 2022, then grew by 18.61% to $3.1 million in 2023, then soared by 79.01% to $5.6 million in 2024, then grew by 1.03% to $5.7 million in 2025.
- Its last three reported values are $5.7 million in Q3 2025, $5.7 million for Q2 2025, and $5.7 million during Q1 2025.